ATE384728T1 - Prodrugs von antiviralen mitteln auf basis von piperazin und substituiertem piperidin - Google Patents

Prodrugs von antiviralen mitteln auf basis von piperazin und substituiertem piperidin

Info

Publication number
ATE384728T1
ATE384728T1 AT05724510T AT05724510T ATE384728T1 AT E384728 T1 ATE384728 T1 AT E384728T1 AT 05724510 T AT05724510 T AT 05724510T AT 05724510 T AT05724510 T AT 05724510T AT E384728 T1 ATE384728 T1 AT E384728T1
Authority
AT
Austria
Prior art keywords
prodrugs
piperazine
antiviral agents
agents based
substituted piperidine
Prior art date
Application number
AT05724510T
Other languages
English (en)
Inventor
Yasutsugu Ueda
Timothy Connolly
John Kadow
Nicholas Meanwell
Tao Wang
Chung-Pin Chen
Kap-Sun Yeung
Zhongxing Zhang
David Kenneth Leahy
Shawn Pack
Nachimuthu Soundararajan
Pierre Sirard
Kathia Levesque
Dominique Thoraval
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34963934&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE384728(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE384728T1 publication Critical patent/ATE384728T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/062—Organo-phosphoranes without P-C bonds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT05724510T 2004-03-15 2005-03-03 Prodrugs von antiviralen mitteln auf basis von piperazin und substituiertem piperidin ATE384728T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55332004P 2004-03-15 2004-03-15
US63523104P 2004-12-10 2004-12-10

Publications (1)

Publication Number Publication Date
ATE384728T1 true ATE384728T1 (de) 2008-02-15

Family

ID=34963934

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05724510T ATE384728T1 (de) 2004-03-15 2005-03-03 Prodrugs von antiviralen mitteln auf basis von piperazin und substituiertem piperidin

Country Status (26)

Country Link
US (12) US7745625B2 (de)
EP (1) EP1725569B1 (de)
JP (1) JP4734318B2 (de)
KR (1) KR101153594B1 (de)
CN (1) CN101941990B (de)
AR (1) AR048039A1 (de)
AT (1) ATE384728T1 (de)
AU (1) AU2005223736C1 (de)
BR (1) BRPI0508876B8 (de)
CA (1) CA2560253C (de)
CY (1) CY1107419T1 (de)
DE (1) DE602005004517T2 (de)
DK (1) DK1725569T3 (de)
ES (1) ES2299022T3 (de)
GE (1) GEP20094736B (de)
HR (1) HRP20080064T5 (de)
IL (1) IL211961A (de)
MY (1) MY139243A (de)
NO (1) NO336742B1 (de)
NZ (2) NZ585294A (de)
PE (1) PE20051151A1 (de)
PL (1) PL1725569T3 (de)
PT (1) PT1725569E (de)
RS (1) RS50567B (de)
TW (1) TWI344843B (de)
WO (1) WO2005090367A1 (de)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040110785A1 (en) * 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
BR0313059B8 (pt) 2002-07-29 2021-07-27 Rigel Pharmaceuticals composto, e, composição farmacêutica
US20050075364A1 (en) * 2003-07-01 2005-04-07 Kap-Sun Yeung Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
CN102358738A (zh) * 2003-07-30 2012-02-22 里格尔药品股份有限公司 2,4-嘧啶二胺化合物及其预防和治疗自体免疫疾病的用途
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US20060100209A1 (en) * 2004-11-09 2006-05-11 Chong-Hui Gu Formulations of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
US20060100432A1 (en) * 2004-11-09 2006-05-11 Matiskella John D Crystalline materials of 1-(4-benzoyl-piperazin-1-yl)-2-[4-methoxy-7-(3-methyl-[1,2,4]triazol-1-yl)-1H-pyrrolo[2,3-c]pyridin-3-yl]-ethane-1,2-dione
JP4801096B2 (ja) * 2005-01-19 2011-10-26 ライジェル ファーマシューティカルズ， インコーポレイテッド ２，４−ピリミジンジアミン化合物のプロドラッグおよびそれらの使用
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7601715B2 (en) * 2005-06-22 2009-10-13 Bristol-Myers Squibb Company Process for preparing triazole substituted azaindoleoxoacetic piperazine derivatives and novel salt forms produced therein
US7396830B2 (en) 2005-10-04 2008-07-08 Bristol-Myers Squibb Company Piperazine amidines as antiviral agents
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
US7501419B2 (en) * 2006-04-25 2009-03-10 Bristol-Myers Squibb Company 4-Squarylpiperazine derivatives as antiviral agents
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US7572810B2 (en) * 2006-06-08 2009-08-11 Bristol-Myers Squibb Company Alkene piperidine derivatives as antiviral agents
US7504399B2 (en) * 2006-06-08 2009-03-17 Bristol-Meyers Squibb Company Piperazine enamines as antiviral agents
EP2687533B1 (de) 2006-07-20 2017-07-19 Debiopharm International SA Acrylamidderivate als FAB-I-Hemmer
ES2389478T3 (es) * 2008-06-25 2012-10-26 Bristol-Myers Squibb Company Derivados de dicetopiperidina como inhibidores de la fijación del VIH
US7960406B2 (en) 2008-06-25 2011-06-14 Bristol-Myers Squibb Company Diketo substituted pyrrolo[2,3-c] pyridines
EP2323633B1 (de) * 2008-09-04 2012-03-21 Bristol-Myers Squibb Company Stabile pharmazeutische zusammensetzung zur optimierten abgabe eines hiv-attachment-inhibitors
US8399513B2 (en) * 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
WO2010047775A2 (en) * 2008-10-20 2010-04-29 Xenoport, Inc. Methods of synthesizing a levodopa ester prodrug
CA2937222C (en) * 2009-06-25 2019-06-04 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds
WO2011056240A2 (en) * 2009-11-09 2011-05-12 Xenoport, Inc. Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
BR112012030818A2 (pt) 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "derivados de ácido c-3 betulínico modificado como inibidores da maturação do hiv"
WO2011153319A1 (en) 2010-06-04 2011-12-08 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
EP2601174B1 (de) 2010-08-06 2014-11-26 Bristol-Myers Squibb Company Substituierte indol- und azaindol-oxoacetylpiperazinamidderivate
WO2012075235A1 (en) 2010-12-02 2012-06-07 Bristol-Myers Squibb Company Alkyl amides as hiv attachment inhibitors
HRP20151212T1 (hr) 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
JP6001560B2 (ja) 2011-01-31 2016-10-05 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｈｉｖ成熟阻害活性を有するｃ−１７およびｃ−３修飾トリテルペノイド
CN103339130B (zh) 2011-01-31 2015-05-06 百时美施贵宝公司 制备hiv附着抑制剂前药化合物的方法及中间体
ES2636312T3 (es) 2011-04-12 2017-10-05 VIIV Healthcare UK (No.5) Limited Derivados de tioamida, amidoxima y amidrazona como inhibidores de la fijación del VIH
WO2013033061A1 (en) 2011-08-29 2013-03-07 Bristol-Myers Squibb Company Fused bicyclic diamine derivatives as hiv attachment inhibitors
US8664213B2 (en) 2011-08-29 2014-03-04 Bristol-Myers Squibb Company Spiro bicyclic diamine derivatives as HIV attachment inhibitors
CA2849475A1 (en) 2011-09-21 2013-03-28 Bristol-Myers Squibb Company Novel betulinic acid derivatives with antiviral activity
WO2013078118A1 (en) 2011-11-21 2013-05-30 Bristol-Myers Squibb Company Methods for determining the susceptibility of a virus to an attachment inhibitor
US8426450B1 (en) * 2011-11-29 2013-04-23 Helsinn Healthcare Sa Substituted 4-phenyl pyridines having anti-emetic effect
US9248139B2 (en) 2011-12-21 2016-02-02 Bristol-Myers Squibb Company Co-processing method and formulations for HIV attachment inhibitor prodrug compound and excipients
MX352320B (es) * 2012-02-08 2017-11-21 Viiv Healthcare Uk No 4 Ltd Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana.
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
WO2013138436A1 (en) 2012-03-14 2013-09-19 Bristol-Myers Squibb Company Cyclolic hydrazine derivatives as hiv attachment inhibitors
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
SMT201900411T1 (it) 2012-06-19 2019-09-09 Debiopharm Int Sa Derivati di profaramci di (e)-n-metil-n-((3-metilbenzofuran-2-il)metil -3-(7-osso-5,6,7,8-tetraidro-1,8-naftiridin-3-il)acrilammide
US9505752B2 (en) 2012-08-09 2016-11-29 Viiv Healthcare Uk (No. 5) Limited Piperidine amide derivatives as HIV attachment inhibitors
EP2895472B1 (de) 2012-08-09 2016-11-23 VIIV Healthcare UK (No.5) Limited Trizyklische Alken-Derivate als HIV-Bindungsinhibitoren
EA027371B1 (ru) 2013-02-06 2017-07-31 Бристол-Майерс Сквибб Компани C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
JP6186012B2 (ja) 2013-02-25 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ−３アルキルおよびアルケニル修飾ベツリン酸誘導体
WO2014160689A1 (en) * 2013-03-27 2014-10-02 Bristol-Myers Squibb Company Piperazine and homopiperazine derivatives as hiv attachment inhibitors
PT2978763T (pt) * 2013-03-27 2018-04-16 Viiv Healthcare Uk No 5 Ltd Derivados de 2-cetoamida como inibidores da ligação do vih
NZ724644A (en) 2014-04-11 2023-07-28 Viiv Healthcare Uk No 4 Ltd Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
EP3218387A1 (de) 2014-11-14 2017-09-20 VIIV Healthcare UK (No.5) Limited Oxolupenderivate
BR112017009852A2 (pt) 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, usos de um composto
CA2971096A1 (en) 2014-12-18 2016-06-23 ViiV Healthcare UK (No.4) Limited A process for preparing halogenated azaindole compounds using pybrop
JP6554542B2 (ja) 2014-12-18 2019-07-31 ヴィーブ ヘルスケア ユーケー（ナンバー４）リミテッド ボロキシンを使用してハロゲン化アザインドール化合物を調製するための方法
CN107428798A (zh) 2015-04-14 2017-12-01 Viiv保健英国第四有限公司 生产hiv成熟抑制剂的方法
DK3355884T3 (da) 2015-10-01 2021-08-02 Olema Pharmaceuticals Inc Tetrahydro-1h-pyrido[3,4-b]indol-antiøstrogenlægemidler
CN108473516B (zh) * 2015-12-14 2021-06-18 马克斯·普朗克科学促进协会 3,5-二苯基-二唑化合物的水溶性衍生物
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3411033A1 (de) 2016-02-04 2018-12-12 ViiV Healthcare UK (No.5) Limited Fostemsavir zur verwendung bei mehrfach vorbehandelten hiv-1-infizierten personen
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
IL313710A (en) 2017-11-21 2024-08-01 Pfizer Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
EP3911651B1 (de) 2019-01-17 2024-01-10 ViiV Healthcare UK (No.4) Limited Verfahren zur herstellung von fostemsavir
FI3923914T3 (fi) 2019-02-14 2023-04-27 Debiopharm Int Sa Afabisiiniformulaatio, menetelmä sen valmistamiseksi
MA56184A (fr) 2019-06-14 2022-04-20 Debiopharm Int Sa Afabicine pour utilisation dans le traitement d'infections bactériennes impliquant un biofilm
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
US20240425568A1 (en) 2021-12-17 2024-12-26 Viiv Healthcare Company Combination therapies for hiv infections and uses thereof
UY40507A (es) 2022-11-02 2024-04-30 Viiv Healthcare Uk No 5 Ltd Proteínas de unión a antígeno
WO2025229018A1 (en) 2024-04-30 2025-11-06 VIIV Healthcare UK (No.5) Limited Neutralizing antibody constructs against hiv
TW202607015A (zh) 2024-04-30 2026-02-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 抗原結合蛋白

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5619238A (en) 1992-07-24 1997-04-08 Canon Kabushiki Kaisha Method of making replaceable ink cartridge
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US20020061892A1 (en) * 2000-02-22 2002-05-23 Tao Wang Antiviral azaindole derivatives
US6476034B2 (en) 2000-02-22 2002-11-05 Bristol-Myers Squibb Company Antiviral azaindole derivatives
WO2002004440A1 (en) * 2000-07-10 2002-01-17 Bristol-Myers Squibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
US20030207910A1 (en) 2001-02-02 2003-11-06 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
RU2303038C2 (ru) * 2001-02-02 2007-07-20 Бристол-Маерс Сквибб Компани Азаиндолоксоуксусные производные пиперазины и фармацевтическая композиция на их основе
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
WO2003082881A2 (en) 2002-03-28 2003-10-09 Procyon Biopharma Inc. Pyridoxal-5-phosphate derivatives as hiv integrase inhibitors
US7745625B2 (en) * 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
US7776863B2 (en) 2004-03-24 2010-08-17 Bristol-Myers Squibb Company Methods of treating HIV infection
US7130185B2 (en) * 2004-06-02 2006-10-31 Research In Motion Limited Handheld computing device having drop-resistant LCD display
US7723338B2 (en) * 2005-01-31 2010-05-25 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4,7-dimethoxy-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-yl]-1,2-dioxoethyl]-piperazine
US7851476B2 (en) * 2005-12-14 2010-12-14 Bristol-Myers Squibb Company Crystalline forms of 1-benzoyl-4-[2-[4-methoxy-7-(3-methyl-1H-1,2,4-triazol-1-YL)-1-[(phosphonooxy)methyl]-1H-pyrrolo[2,3-C]pyridin-3-YL]-1,2-dioxoethyl]-piperazine
CN103339130B (zh) * 2011-01-31 2015-05-06 百时美施贵宝公司 制备hiv附着抑制剂前药化合物的方法及中间体
MX352320B (es) * 2012-02-08 2017-11-21 Viiv Healthcare Uk No 4 Ltd Metodos para la preparacion del compuesto profarmaco de piperazina inhibidor de la union de virus de inmunodeficiencia humana.

Also Published As

Publication number Publication date
US20150232414A1 (en) 2015-08-20
US20200046743A1 (en) 2020-02-13
US20180000849A1 (en) 2018-01-04
AU2005223736B2 (en) 2011-05-26
PT1725569E (pt) 2008-03-28
BRPI0508876B1 (pt) 2020-05-26
MY139243A (en) 2009-09-30
WO2005090367A1 (en) 2005-09-29
US20160361328A1 (en) 2016-12-15
RU2374256C2 (ru) 2009-11-27
KR101153594B1 (ko) 2012-07-05
US8461333B2 (en) 2013-06-11
EP1725569A1 (de) 2006-11-29
GEP20094736B (en) 2009-07-27
RS50567B (sr) 2010-05-07
HRP20080064T5 (en) 2008-10-31
US20210023098A1 (en) 2021-01-28
US8168615B2 (en) 2012-05-01
AU2005223736A1 (en) 2005-09-29
US7745625B2 (en) 2010-06-29
PL1725569T3 (pl) 2008-09-30
CN101941990A (zh) 2011-01-12
JP2007529519A (ja) 2007-10-25
US11369624B2 (en) 2022-06-28
IL211961A (en) 2013-08-29
NZ585294A (en) 2011-09-30
RU2006136390A (ru) 2008-04-27
CA2560253A1 (en) 2005-09-29
TWI344843B (en) 2011-07-11
TW200600096A (en) 2006-01-01
BRPI0508876A (pt) 2007-09-04
US20120238755A1 (en) 2012-09-20
US20050209246A1 (en) 2005-09-22
NO336742B1 (no) 2015-10-26
PE20051151A1 (es) 2006-01-20
HRP20080064T3 (hr) 2008-03-31
JP4734318B2 (ja) 2011-07-27
US20130253196A1 (en) 2013-09-26
AR048039A1 (es) 2006-03-22
CN101941990B (zh) 2012-04-25
HK1148533A1 (en) 2011-09-09
CA2560253C (en) 2013-01-15
NO20064062L (no) 2006-12-08
HK1096687A1 (en) 2007-06-08
US8871771B2 (en) 2014-10-28
ES2299022T3 (es) 2008-05-16
US20190111066A1 (en) 2019-04-18
CY1107419T1 (el) 2012-12-19
DE602005004517D1 (de) 2008-03-13
KR20060129533A (ko) 2006-12-15
NZ549867A (en) 2010-07-30
DE602005004517T2 (de) 2009-01-22
US20150315218A1 (en) 2015-11-05
BRPI0508876B8 (pt) 2021-05-25
EP1725569B1 (de) 2008-01-23
AU2005223736C1 (en) 2011-10-06
DK1725569T3 (da) 2008-06-02
US20150025240A1 (en) 2015-01-22
US20100210599A1 (en) 2010-08-19

Similar Documents

Publication Publication Date Title
DE602005004517D1 (de) Prodrugs von antiviralen mitteln auf basis von piperazin und substituiertem piperidin
BRPI0817644A2 (pt) Derivados de piperidina e piperazina
ATE382611T1 (de) Piperazin mit or-substituierter phenylgruppe und deren verwendung als glyt1-inhibitoren
ATE398126T1 (de) Azaindolinhibitoren von mtp und apob
ATE397860T1 (de) Fungizide mischungen auf der basis von prothioconazole und picoxystrobin
ATE523506T1 (de) Amingebundene pyridyl- und phenylsubstituierte piperazin-piperidine mit cxcr3-antagonistischer aktivität
DE602005012267D1 (de) N von geräten
NO20043709L (no) Nye aryl- og heteroarylpiperaziner
EP1788874A4 (de) Salze von 5-azacytidin
IS2402B (is) Píperidínafleiður
ATE440093T1 (de) 1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
ATE405573T1 (de) Amid-prodrug von gemcitabin, zusammensetzungen und verwendung damit
ATE384054T1 (de) Substituierte benzoxazinones und ihre verwendung
ATE479681T1 (de) Substituierte piperidine
DE602005019873D1 (de) Kristalline formen von duloxetin als freie base
ATE430475T1 (de) Fungizide mischungen auf grundlage von carbamatderivaten und insektiziden
ATE486878T1 (de) Benzothienopyridine zur verwendung als inhibitoren von eg5-kinesin
EP1885919A4 (de) Methylierung und expression von genen
DE60202519D1 (de) Fungizide zusammensetzungen auf der basis von pyridylmethylbenzamid-derivaten und propamocarb
DE502004006418D1 (de) Heterocyclyl-substituierte dihydrochinazoline und ihre verwendung als antivirale mittel
DE602004024264D1 (de) Verbesserung von Stabilität und Antwortverhalten von Regelungssystemen
DE50311496D1 (de) Neue arzneimittelkompositionen auf der basis von anticholinergika und egfr-kinase-hemmern
DE502005000018D1 (de) Vernetzbare Massen auf der Basis von Organosiliciumverbindungen
EP1919479A4 (de) Melanocortin rezeptorspezifisches piperazin und keto-piperazin-verbindungen
ATE441647T1 (de) N-amidderivate von 8-azabicycloä3.2.1üoct-3-yl als ccr1-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1725569

Country of ref document: EP